In a human study of paired synovial fluid mononuclear cells (SFMCs) from patients with RA, psoriatic arthritis, and spondylarthritis, MTX and other DMARDs were used and decreased MCP-1 production [58]. This evidence concerns the gene CCL2 and rheumatoid arthritis.